eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2011
vol. 15
 
Share:
Share:
more
 
 
abstract:
Review paper

Optimal chemotherapy treatment for patients with advanced colorectal cancer

Rafał Stec
,
Lubomir Bodnar
,
Marta Smoter
,
Michał Mączewski
,
Cezary Szczylik

Contemporary Oncology (2011) vol. 15; 1 (31–39)
Online publish date: 2011/03/11
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Colorectal cancer (CRC) is one of the most common malignancies in the world. Each year one million new cases are diagnosed and about 500 000 people die of this disease. Due to the development of research in clinical oncology, many new antineoplastic agents are registered and available in the treatment of CRC, for example irinotecan, oxaliplatin, 5-fluorouracil, capecitabine, and the monoclonal antibodies bevacizumab, panitumumab and cetuximab. Introduction of molecularly targeted therapies caused prolongation of median time to progression of the disease as well as median overall survival. The best sequence of the therapeutic options for the achievement of the patients’ benefits and good tolerance of the treatment has not been established. This article contains a review of randomized phase II/III studies and registration trials regarding systemic treatment of CRC. The authors have attempted to translate the results of the studies into treatment optimization.
keywords:

colorectal cancer, palliative chemotherapy, bevacizumab, panitumumab, cetuximab

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe